InternationalUSRemember you can easily switch between MIP US and MIP International at any time

European Commission claims pharma competition success

Legal Media Group


The proportion of problematic patent settlements in the pharmaceutical industry has fallen, even though the number of settlements has grown, according to the European Commission

In a statement published on January 31, the Commission said that its third annual survey had found that 11% of antitrust settlements were potentially problematic from an antitrust point of view, compared to 21% when the pharmaceutical sector enquiry was...


Please log in to read the rest of this article.

New to Managing Intellectual Property? Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.

Already registered?

Please make sure you log in to read the rest of the article.

Log in

Join us now

Gain FREE access to up to five free articles when you register now.

Join here

profile

Managing IP

ManagingIP

ManagingIP profile

@schestowitz Well, we do what we think is most appropriate & useful for our readers. Can't speak for others.

Apr 28 2017 04:43 ·  reply ·  retweet ·  favourite
ManagingIP profile

@schestowitz It's true that we have sought interviews with AMBA (not specifically on UPC) and permission was refused by the EPO president.

Apr 28 2017 04:41 ·  reply ·  retweet ·  favourite
ManagingIP profile

@schestowitz However, we have also given space to voices critical of UPC & Unitary Patent, eg in Spain & Poland https://t.co/QXiPQknzDg

Apr 28 2017 04:38 ·  reply ·  retweet ·  favourite
More from the Managing IP blog


April 2017

Patent subject matter eligibility: A new Section 101

Calls for changing Section 101 of the Patent Act in the US are increasing. A proposed amendment from IPO shows one way to do it, reports Michael Loney



Most read articles

Supplements